

01 December 2025

## Treatments for Oncology

**Q1. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:**

- Atezolizumab (Tecentriq) <5
- Durvalumab (Imfinzi) <5
- Nivolumab (Opdivo) <5 (single agent)
- Pembrolizumab (Keytruda) 16
- Chemotherapy
  - Alectinib (NSCLC) <5
  - Cisplatin & Vinorelbine (NSCLC) <5
  - Crizotinib 84 day (NSCLC) <5
  - Docetaxel (NSCLC) <5
  - Gefitinib (NSCLC) <5
  - Gemcitabine & Carboplatin (NSCLC) <5
  - Nivolumab/Paclitaxel/Carboplatin (NSCLC) <5
  - Osimertinib & Pemetrexed/Carboplatin (NSCLC) <5
  - Paclitaxel & Carboplatin (NSCLC) <5
  - Pembrolizumab/Gemcitabine/Carbo (NSCLC) <5
  - Pembrolizumab/Paclitaxel/Carbo (NSCLC) <5
  - Pembrolizumab/Pemetrexed/Carbo (NSCLC) 6
  - Pembrolizumab/Pemetrexed/Carboplatin (Metastatic) (NSCLC) <5
  - Pembrolizumab/Pemetrexed/Carboplatin Neo-adj/Adj (NSCLC) <5
  - Pemetrexed & Carboplatin (NSCLC) <5
  - Vinorelbine & Carboplatin (NSCLC) <5
- Radiotherapy 51 patients with a treatment protocol of "NSCLC".  
 These are a mixture of Radical & Palliative.
- Chemotherapy AND Radiotherapy
  - Carboplatin & Vinorelbine XRT (NSCLC) 6
  - Paclitaxel & Carboplatin XRT (NSCLC) 6
  - Cisplatin & Vinorelbine XRT (NSCLC) <5
- Osimertinib 9

**Q2. How many patients has your trust treated in the last 3 months with Pembrolizumab for stage II Melanoma?**

46

We are unable to provide an exact figure where numbers are very low, <5. To provide this level of information would reduce numbers to discoverable limits where the patients could be identifiable. This is because many of these drugs are high cost and prescribed on a named patient basis. Pharmaceutical companies, would be aware of this.

**01 December 2025**

This is exempt from release under section 40(2) Personal Information relating to a third party, of the FOI Act.

Disclosure would constitute a breach of the principles of the Data Protection Act 2018.